Aprea Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
TPG Capital acquisition of Convey Health Solutions and related financing
Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of Convey Health Solutions from New Mountain Capital and related…
Davis Polk Advises the Goldman Sachs Merchant Banking Division on Its Investment in MedVet
Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet.
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…
Atreca $125 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on…
Personalis, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
TransMedics Group, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…